The Role of Fc Receptors in the Therapeutic anti-tumor Activity of Checkpoint Antibodies

Immunomodulatory mAbs are revolutionizing cancer treatment due to their clinical effective stimulation of therapeutic anti-cancer immunity. Recent studies demonstrated the importance of the Fc domain of these types of mAbs. Their optimal activity can be critically depended on their ability to engage defined FcgR pathways. I will discuss our recent characterization of these FcgR-dependent mechanisms, and how they can be exploit to design 2^ndgeneration Fc-optimized immunomodulatory mAbs.